Guggenheim Sees Zontivity and Toprol XL Bolstering Growth for Aralez Pharma (ARLZ); Affirms at 'Buy'
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Guggenheim affirms Aralez Pharmaceuticals (Nasdaq: ARLZ) at Buy with a price target of $12 following a recently-updated financial model.
Analyst Louise Chen sees Aralez being EBITDA positive by 2017. The analyst commented:
We updated our financial model to include sales for Zontivity and Toprol XL, two acquired drugs that will enhance ARZL's cardiovascular (CV) drug franchise, which currently includes Yosprala and Fibricor. We believe the Street still underestimates the earnings potential of ARLZ's CV franchise, and we believe Yosprala peak sales of $200MM+ by '22 are not fully reflected in consensus expectations yet. Additionally, we think ARLZ will be a successful consolidator of assets with its strong balance sheet, experienced management team, and low tax rate. We also modestly reduced our 3Q16 Vimovo royalty estimate, which decreased our 3Q16 EPS slightly.
FY17 revenue moves from $87.2 million up to $129.6 million and EPS was adjusted from ($0.70) out to ($0.80).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA/Merrill Lynch Upgrades CF Industries (CF) to Buy, Says "Consensus Estimates Now Beatable"
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Signet Jewelers (SIG) May Be Close To Selling Credit Business, Likely Positive For Stock - Northcoast Research
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesEarnings, Louise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!